文献速递白血病造血干细胞移植与细胞治疗

BET抑制剂通过增强白血病来源终末耗竭CD8+ T细胞中TCF7的可及性逆转抗PD1耐药

BET inhibitors rescue anti-PD1 resistance by enhancing TCF7 accessibility in leukemia-derived terminally exhausted CD8+ T cells.
PubMed 文献 · Leukemia · 2023-01-21

研究在急性髓系白血病(AML)小鼠模型及患者细胞中发现耗竭CD8+ T细胞(TEx),BET抑制剂(BETi)体外可逆转CD8+ T细胞耗竭并恢复增殖能力,与抗PD1联用增强该效应;体内BETi与抗PD1协同减少循环白血病细胞、富集骨髓CD8+ T细胞并上调Tcf7、Slamf6、Cxcr5表达;单细胞ATAC-seq显示JQ1增加TEx细胞中Tcf7可及性,提示BETi通过解除对TEx CD8+ T细胞祖程序抑制发挥作用。

要点

  • AML小鼠和患者来源细胞经BETi体外处理可逆转CD8+ T细胞耗竭并恢复增殖能力。
  • BETi联合抗PD1体外增强逆转耗竭效应,体内协同减少循环白血病细胞并富集骨髓CD8+ T细胞。
  • 单细胞ATAC-seq显示JQ1特异性增加TEx细胞中Tcf7可及性,提示表观遗传机制。

核心结论

  • BETi可逆转CD8+ T细胞耗竭并克服免疫检查点阻断(ICB)耐药,机制可能为解除对TEx CD8+ T细胞祖程序的抑制并维持抗PD1响应性CD8+ T细胞池。

研究设计与样本

  • 研究使用AML小鼠模型及AML患者来源细胞,进行体外BETi处理、体内BETi联合抗PD1治疗,并对体内JQ1处理的AML来源CD8+ T细胞进行单细胞ATAC-seq表观基因组分析。

主要发现

  • AML小鼠和患者细胞经BETi体外处理可逆转CD8+ T细胞耗竭,恢复增殖能力并扩增功能更强的前体耗竭T细胞,联合BETi与抗PD1增强该逆转。
  • 体内BETi与抗PD1协同减少循环白血病细胞、富集骨髓CD8+ T细胞,并增加CD8+ T细胞中Tcf7、Slamf6和Cxcr5表达。
  • 单细胞ATAC-seq显示JQ1在TEx细胞中特异性增加Tcf7可及性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Many acute myeloid leukemia (AML) patients exhibit hallmarks of immune exhaustion, such as increased myeloid-derived suppressor cells, suppressive regulatory T cells and dysfunctional T cells. Similarly, we have identified the same immune-related features, including exhausted CD8+ T cells (TEx) in a mouse model of AML. Here we show that inhibitors that target bromodomain and extra-terminal domain (BET) proteins affect tumor-intrinsic factors but also rescue T cell exhaustion and ICB resistance. Ex vivo treatment of cells from AML mice and AML patients with BET inhibitors (BETi) reversed CD8+ T cell exhaustion by restoring proliferative capacity and expansion of the more functional precursor-exhausted T cells. This reversal was enhanced by combined BETi and anti-PD1 treatment. BETi synergized with anti-PD1 in vivo, resulting in the reduction of circulating leukemia cells, enrichment of CD8+ T cells in the bone marrow, and increase in expression of Tcf7, Slamf6, and Cxcr5 in CD8+ T cells. Finally, we profiled the epigenomes of in vivo JQ1-treated AML-derived CD8+ T cells by single-cell ATAC-seq and found that JQ1 increases Tcf7 accessibility specifically in Tex cells, suggesting that BETi likely acts mechanistically by relieving repression of progenitor programs in Tex CD8+ T cells and maintaining a pool of anti-PD1 responsive CD8+ T cells.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Romine KA, MacPherson K, Cho HJ, et al. BET inhibitors rescue anti-PD1 resistance by enhancing TCF7 accessibility in leukemia-derived terminally exhausted CD8+ T cells. Leukemia. 2023. PMID: 36681742. doi:10.1038/s41375-023-01808-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。